Prospects for combining hormonal and nonhormonal growth factor inhibition

Clinical Cancer Research

Volumn 7, Issue , 2001, Pages 4350s-4355s

  Wakeling, A E ^a   Nicholson, R I ^b   Gee, J M W ^b  

^a ASTRAZENECA   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; FULVESTRANT; GEFITINIB; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RALOXIFENE; SOMATOMEDIN; TAMOXIFEN; TOREMIFENE; TRASTUZUMAB;

ANGIOGENESIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL SURFACE; CELL SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; ENZYME ACTIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG THERAPY, COMBINATION; EPIDERMAL GROWTH FACTOR; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; QUINAZOLINES; TAMOXIFEN;

EID: 0035664874     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. ICI 182, 780 (Faslodex™) development of a novel "pure" antiestrogen
2. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer
3. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
4. The type I growth factor receptors in human breast cancer
5. Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy
6. The EGF receptor family as targets for cancer therapy
7. How receptor tyrosine kinases activate Ras
8. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
9. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor
10. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines
11. Small molecule inhibitors of receptor tyrosine kinases
12. Studies leading to the identification of ZD1839 (Iressa™): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
13. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
14. Molecular mechanisms of action of steroid/thyroid receptor superfamily members
15. The molecular pharmacology of SERMs
16. A potent specific pure antiestrogen with clinical potential
17. Action of "pure" antiestrogens in inhibiting estrogen receptor action
18. Similarities and distinctions in the mode of action of different classes of antiestrogens
19. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth
20. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer
21. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens
22. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer
23. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
24. A double blind, randomized trial comparing the efficacy and tolerability of ’Faslodex’ (fulvestrant) with ’Arimidex’ (anastrozole) in post-menopausal women with advanced breast cancer
25. ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development
26. ZD1839 (’IRESSA’) a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): Inhibition of C-FOS mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition
27. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
28. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by co-administration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
29. ZD1839 (’Iressa’), a novel epidermal growth factor receptor tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression
30. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182, 780 (Faslodex)
31. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation
32. An epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (ZD1839) inhibits proliferation in normal and preinvasive epithelia
33. Epidermal growth factor receptor tyrosine kinase inhibition by ZD1839 (’Iressa’) blocks oestrogen-stimulated proliferation and progesterone receptor expression in human breast epithelium
34. Intermittent oral Zd1839 (’Iressa’), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a Phase I study
35. Continuous administration of ZD1839 (’Iressa’), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability
36. ZD1839 (’Iressa’) as an anticancer agent
37. Ligand-independent activation of steroid receptors: New rules for old players
38. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer
39. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells
40. Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2
41. A rationale for the use of small molecule EGF receptor tyrosine kinase inhibitors against HER2/neu (erbB2) overexpressing breast tumor cells
42. EGFR tyrosine kinase inhibition decreases epithelial proliferation in DCIS of the breast, whereas c-erbB2 blockade does not